Peter Blume-Jensen
President and CEO at Acrivon Therapeutics Inc.
Sits on 1 board. Last updated September 28, 2026
Time on boards
- Boards served
- 1
- Current seats
- 1
- Board service
- 3 years
- Director since
- 2023
3 years of board service in total across 1 board, counting each seat separately. Longest: Acrivon Therapeutics Inc., 3 years.
Acrivon Therapeutics Inc.
Director · President and CEO
Chief executive roles
Acrivon Therapeutics Inc.
· President and CEO
Dates unknown
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| May 18, 2026 | Acrivon Therapeutics Inc. | Grant or award | +180,095 | — | — |
| May 18, 2026 | Acrivon Therapeutics Inc. | Grant or award | +72,706 | — | — |
| May 14, 2026 | Acrivon Therapeutics Inc. | Shares withheld for tax | −1,253 | $1.92 | $2,406 |
| May 14, 2026 | Acrivon Therapeutics Inc. | Shares withheld for tax | −490 | $1.92 | $941 |
| Feb 21, 2026 | Acrivon Therapeutics Inc. | Shares withheld for tax | −14,265 | $1.53 | $21,825 |
| Feb 14, 2026 | Acrivon Therapeutics Inc. | Shares withheld for tax | −1,302 | $1.63 | $2,122 |
| Feb 14, 2026 | Acrivon Therapeutics Inc. | Shares withheld for tax | −579 | $1.63 | $944 |
| Jan 14, 2026 | Acrivon Therapeutics Inc. | Open-market purchase | +49,000 | $1.68 | $82,320 |
| May 21, 2025 | Acrivon Therapeutics Inc. | Shares withheld for tax | −19,904 | $1.15 | $22,890 |
| May 14, 2025 | Acrivon Therapeutics Inc. | Shares withheld for tax | −59,766 | $1.14 | $68,133 |
| May 14, 2025 | Acrivon Therapeutics Inc. | Shares withheld for tax | −491 | $1.14 | $560 |
| Feb 21, 2025 | Acrivon Therapeutics Inc. | Shares withheld for tax | −19,904 | $5.54 | $110,268 |
| Nov 14, 2024 | Acrivon Therapeutics Inc. | Shares withheld for tax | −59,766 | $7.92 | $473,347 |
| Nov 14, 2024 | Acrivon Therapeutics Inc. | Shares withheld for tax | −490 | $7.92 | $3,881 |
| Aug 21, 2024 | Acrivon Therapeutics Inc. | Shares withheld for tax | −79,616 | $9.19 | $731,671 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.